Comments on: Ascletis Submits Two IND Applications to U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35

Comments on: Ascletis Submits Two IND Applications to U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35 https://9krapalm.com/ascletis-submits-two-ind-applications-to-u-s-fda-for-the-treatment-of-obesity-asc36-once-monthly-injection-a-peptide-amylin-receptor-agonist-and-asc36_35-fdc-once-monthly-injection-a-co-formulati/ เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm Mon, 06 Jul 2026 04:04:10 +0000 hourly 1 https://wordpress.org/?v=7.0